Blood Banking & Tissue Typing Facilities in European Union: Market Size, Businesses & Forecast 2026

The Blood Banking & Tissue Typing Facilities industry in the European Union comprises established entities responsible for the collection, testing, processing, storage, and distribution of human blood, blood components, and various human tissues and cells. The sector is moving toward strict regulatory modernization and greater cross-border integration to safeguard public health and ensure stable therapeutic supplies. The operational ecosystem is largely driven by public and non-profit national health systems, alongside private providers of specialized storage and processing services, operating under harmonized quality metrics as of 2026.

Industry snapshot

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Blood Banking & Tissue Typing Facilities in European Union industry cover?

This industry encompasses the specialized infrastructure required to manage substances of human origin intended for clinical or therapeutic use in patients. These facilities secure the supply chain for blood transfusions and cell- or tissue-based transplantations, covering everything from initial donor selection to long-term cryopreservation.

• •Covers blood establishments collecting whole blood and plasma, alongside tissue banks handling musculoskeletal, ophthalmic, and reproductive cells.
• •Utilizes specialized software and unique identification frameworks like the Single European Code (SEC) to ensure full traceability from donor to recipient.
• •Includes advanced laboratory testing for histocompatibility and immunogenetics (tissue typing) to guarantee patient-donor compatibility before transplantation.

Who operates in the industry and how is it structured?

The European Union's market structure is highly distinct, characterized by a dominant public-sector or non-profit presence mixed with specialized private commercial facilities. National blood transfusion services run by state agencies or organizations like the Red Cross govern the majority of blood collections, while private companies frequently manage cord blood banking, specialized tissue processing, and advanced cell therapies.

• •Non-profit and public health establishments manage the vast majority of whole blood collections based on voluntary, unpaid donations.
• •Private commercial operators are heavily concentrated in specialized segments, including autologous stem cell storage and private cord blood banking.
• •Facilities frequently collaborate across borders via network organizations such as the European Blood Alliance (EBA) to optimize plasma and blood component logistics.

What drives demand in the industry?

The primary demand drivers are structural clinical needs and demographic shifts across Europe. Chronic disease prevalence, complex surgeries, and an aging population require a continuous, high-volume flow of blood products and tissue implants.

• •Demographic aging significantly increases demand, with the European Commission projecting a sharp rise in the EU old-age dependency ratio over coming decades.
• •Surgical interventions and complex trauma management account for approximately 40% of standard blood component utilization across European hospitals.
• •Oncology and hematology treatments drive rapid segment growth due to increasing cancer incidences requiring intensive transfusion and marrow support.

Who are the notable companies in the industry?

Competition in the commercial landscape centers on technological capabilities, processing efficiency, and compliance with stringent quality standards. Public and multinational life-sciences corporations operate specialized units or provide the underlying technical infrastructure, distribution, and processing technology used within EU facilities.

• •Merck KGaA operates as a major supplier of specialized tools, consumables, and preservation media used in tissue banking and biobanking applications.
• •Thermo Fisher Scientific Inc. provides high-capacity cryopreservation systems, laboratory instrumentation, and tissue-typing reagents across EU facilities.
• •Qiagen N.V. supplies advanced molecular testing and diagnostics kits used for screening infectious diseases and tissue typing within EU laboratories.
• •Esperite N.V. represents a commercial player traditionally active in European family stem cell and cord blood banking services.

What are the recent trends and outlook?

The industry is adapting to advanced data management frameworks and cross-border data tracking systems. Current focuses include crisis preparedness, minimizing serious adverse reactions, and utilizing big data to track emerging healthcare treatments, such as specialized plasma collections.

• •The European Blood Alliance and the European Commission successfully deployed the Big Data Test Infrastructure (BDTI) to manage convalescent plasma data collections.
• •Facilities submit Serious Adverse Reactions and Events (SARE) annual data to national competent authorities to continuously monitor European tissue safety.
• •Increased focus on precision medicine is accelerating the integration of genetic sequencing directly into routine tissue-typing workflows.

How is the industry regulated?

The regulatory landscape is undergoing a major transition to modernize safety rules and create a more future-proof legal framework. National guidelines are being unified under a sweeping European framework that broadens oversight and harmonizes standard operating conditions across all member states.

• •Regulation (EU) 2024/1938, known as the Substances of Human Origin (SoHO) Regulation, entered into force in 2024 and will apply directly by August 2027.
• •The SoHO Regulation replaces older directives to expand safety frameworks over blood, tissues, cells, human breast milk, and microbiota.
• •Commission Directive (EU) 2015/565 regulates technical requirements for the precise allocation of the Single European Code (SEC) on distributed human tissues.

Government, statistical and trade sources used for this Claight analysis.

• European Commission DG SANTE (Public Health) 2024 ·
• Official Journal of the European Union (Regulation (EU) 2024/1938) ·
• European Blood Alliance (EBA) Resources 2024 ·
• Eurostat Statistical Classification of Economic Activities (NACE Rev. 2)